Report Detail
Global Amifostine Market Insights, Forecast to 2025
- RnM2945318 |
- 14 February, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Amifostine (Ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.
Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.
The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.
Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.
The global Amifostine market is valued at 48 million US$ in 2018 and will reach 57 million US$ by the end of 2025, growing at a CAGR of 2.2% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Amifostine market based on company, product type, end user and key regions.
This report studies the global market size of Amifostine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Amifostine in these regions.
This research report categorizes the global Amifostine market by top players/brands, region, type and end user. This report also studies the global Amifostine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Clinigen Group
Sun Pharmaceutical
Taj Pharmaceuticals
Merro Pharmaceutical
Luye Pharma
Mingren Pharma
Market size by Product
400mg/Dose
500mg/Dose
Market size by End User
Head and Neck Cancer Adjuvant Therapy
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Amifostine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Amifostine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Amifostine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Amifostine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Amifostine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Amifostine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Amifostine Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Amifostine Market Size Growth Rate by Product
- 1.4.2 400mg/Dose
- 1.4.3 500mg/Dose
- 1.5 Market by End User
- 1.5.1 Global Amifostine Market Size Growth Rate by End User
- 1.5.2 Head and Neck Cancer Adjuvant Therapy
- 1.5.3 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Amifostine Market Size
- 2.1.1 Global Amifostine Revenue 2014-2025
- 2.1.2 Global Amifostine Sales 2014-2025
- 2.2 Amifostine Growth Rate by Regions
- 2.2.1 Global Amifostine Sales by Regions
- 2.2.2 Global Amifostine Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Amifostine Sales by Manufacturers
- 3.1.1 Amifostine Sales by Manufacturers
- 3.1.2 Amifostine Sales Market Share by Manufacturers
- 3.1.3 Global Amifostine Market Concentration Ratio (CR5 and HHI)
- 3.2 Amifostine Revenue by Manufacturers
- 3.2.1 Amifostine Revenue by Manufacturers (2014-2019)
- 3.2.2 Amifostine Revenue Share by Manufacturers (2014-2019)
- 3.3 Amifostine Price by Manufacturers
- 3.4 Amifostine Manufacturing Base Distribution, Product Types
- 3.4.1 Amifostine Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Amifostine Product Type
- 3.4.3 Date of International Manufacturers Enter into Amifostine Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Amifostine Sales by Product
- 4.2 Global Amifostine Revenue by Product
- 4.3 Amifostine Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Amifostine Breakdown Data by End User
6 North America
- 6.1 North America Amifostine by Countries
- 6.1.1 North America Amifostine Sales by Countries
- 6.1.2 North America Amifostine Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Amifostine by Product
- 6.3 North America Amifostine by End User
7 Europe
- 7.1 Europe Amifostine by Countries
- 7.1.1 Europe Amifostine Sales by Countries
- 7.1.2 Europe Amifostine Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Amifostine by Product
- 7.3 Europe Amifostine by End User
8 Asia Pacific
- 8.1 Asia Pacific Amifostine by Countries
- 8.1.1 Asia Pacific Amifostine Sales by Countries
- 8.1.2 Asia Pacific Amifostine Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Amifostine by Product
- 8.3 Asia Pacific Amifostine by End User
9 Central & South America
- 9.1 Central & South America Amifostine by Countries
- 9.1.1 Central & South America Amifostine Sales by Countries
- 9.1.2 Central & South America Amifostine Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Amifostine by Product
- 9.3 Central & South America Amifostine by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Amifostine by Countries
- 10.1.1 Middle East and Africa Amifostine Sales by Countries
- 10.1.2 Middle East and Africa Amifostine Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Amifostine by Product
- 10.3 Middle East and Africa Amifostine by End User
11 Company Profiles
- 11.1 Clinigen Group
- 11.1.1 Clinigen Group Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Clinigen Group Amifostine Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Clinigen Group Amifostine Products Offered
- 11.1.5 Clinigen Group Recent Development
- 11.2 Sun Pharmaceutical
- 11.2.1 Sun Pharmaceutical Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Sun Pharmaceutical Amifostine Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Sun Pharmaceutical Amifostine Products Offered
- 11.2.5 Sun Pharmaceutical Recent Development
- 11.3 Taj Pharmaceuticals
- 11.3.1 Taj Pharmaceuticals Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Taj Pharmaceuticals Amifostine Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Taj Pharmaceuticals Amifostine Products Offered
- 11.3.5 Taj Pharmaceuticals Recent Development
- 11.4 Merro Pharmaceutical
- 11.4.1 Merro Pharmaceutical Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Merro Pharmaceutical Amifostine Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Merro Pharmaceutical Amifostine Products Offered
- 11.4.5 Merro Pharmaceutical Recent Development
- 11.5 Luye Pharma
- 11.5.1 Luye Pharma Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Luye Pharma Amifostine Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Luye Pharma Amifostine Products Offered
- 11.5.5 Luye Pharma Recent Development
- 11.6 Mingren Pharma
- 11.6.1 Mingren Pharma Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Mingren Pharma Amifostine Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Mingren Pharma Amifostine Products Offered
- 11.6.5 Mingren Pharma Recent Development
12 Future Forecast
- 12.1 Amifostine Market Forecast by Regions
- 12.1.1 Global Amifostine Sales Forecast by Regions 2019-2025
- 12.1.2 Global Amifostine Revenue Forecast by Regions 2019-2025
- 12.2 Amifostine Market Forecast by Product
- 12.2.1 Global Amifostine Sales Forecast by Product 2019-2025
- 12.2.2 Global Amifostine Revenue Forecast by Product 2019-2025
- 12.3 Amifostine Market Forecast by End User
- 12.4 North America Amifostine Forecast
- 12.5 Europe Amifostine Forecast
- 12.6 Asia Pacific Amifostine Forecast
- 12.7 Central & South America Amifostine Forecast
- 12.8 Middle East and Africa Amifostine Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Amifostine Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Amifostine . Industry analysis & Market Report on Amifostine is a syndicated market report, published as Global Amifostine Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Amifostine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
